APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pharmacogenomics Technology (Theranostics & CDx)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pharmacogenomics Technology (Theranostics & CDx) Market Outlook and Growth Opportunities 2026

29 December 2025193 pages

Choose your research edition.

Industry ResearchPharmacogenomics Technology (Theranostics & CDx) Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Pharmacogenomics Technology (Theranostics & CDx) Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Pharmacogenomics Technology (Theranostics & CDx) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pharmacogenomics Technology (Theranostics & CDx) Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Pharmacogenomics Technology (Theranostics & CDx) Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Global Pharmacogenomics Technology (Theranostics & CDx) key players include Illumina, F. Hoffmann-La Roche, Agilent, Abbott, Thermo Fisher Scientific etc. Global top three players hold a share over 65%. North America is the largest market, with a share about 40%, followed by Europe and China, both have a share about 40 percent.

This report provides an overview of the global Pharmacogenomics Technology (Theranostics & CDx) market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pharmacogenomics Technology (Theranostics & CDx) and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

Read the full market overview

The report also presents Pharmacogenomics Technology (Theranostics & CDx) revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Pharmacogenomics Technology (Theranostics & CDx) market.

Pharmacogenomics Technology (Theranostics & CDx) Segment by Company

Illumina

F. Hoffmann-La Roche

Agilent

Abbott

Thermo Fisher Scientific

Qiagen

Guardant Health

MGI Tech

Amoy Diagnostics

BGI Group

Pharmacogenomics Technology (Theranostics & CDx) Segment by Type

Instruments

Reagents and Consumables

Other

Pharmacogenomics Technology (Theranostics & CDx) Segment by Application

Tumour

Diabetes

Mental Illness

Cardiovascular Disease

Other

Pharmacogenomics Technology (Theranostics & CDx) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pharmacogenomics Technology (Theranostics & CDx) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Pharmacogenomics Technology (Theranostics & CDx) key companies, revenue, market share, and recent developments.

3. To split the Pharmacogenomics Technology (Theranostics & CDx) breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Pharmacogenomics Technology (Theranostics & CDx) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pharmacogenomics Technology (Theranostics & CDx) significant trends, drivers, influence factors in global and regions.

6. To analyze Pharmacogenomics Technology (Theranostics & CDx) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmacogenomics Technology (Theranostics & CDx) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pharmacogenomics Technology (Theranostics & CDx) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmacogenomics Technology (Theranostics & CDx).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pharmacogenomics Technology (Theranostics & CDx) industry.

Chapter 3: Detailed analysis of Pharmacogenomics Technology (Theranostics & CDx) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Pharmacogenomics Technology (Theranostics & CDx) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Pharmacogenomics Technology (Theranostics & CDx) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pharmacogenomics Technology (Theranostics & CDx) Industry Trends Table 2. Pharmacogenomics Technology (Theranostics & CDx) Industry Drivers Table 3. Pharmacogenomics Technology (Theranostics & CDx) Industry Opportunities and Challenges Table 4. Pharmacogenomics Technology (Theranostics & CDx) Industry Restraints Table 5. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Company (2021-2026) Table 7. Global Pharmacogenomics Technology (Theranostics & CDx) Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Pharmacogenomics Technology (Theranostics & CDx) Key Company Manufacturing Base & Headquarters Table 9. Global Pharmacogenomics Technology (Theranostics & CDx) Company, Product Type & Application Table 10. Global Pharmacogenomics Technology (Theranostics & CDx) Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Pharmacogenomics Technology (Theranostics & CDx) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Instruments Table 15. Significant Companies of Reagents and Consumables Table 16. Significant Companies of Other Table 17. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type (2021-2026) Table 21. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Tumour Table 23. Significant Companies of Diabetes Table 24. Significant Companies of Mental Illness Table 25. Significant Companies of Cardiovascular Disease Table 26. Significant Companies of Other Table 27. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application (2021-2026) Table 31. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application (2027-2032) Table 32. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Region (2021-2026) Table 35. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Region (2027-2032) Table 37. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value Market Share by Country (2021-2026) Table 40. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value Market Share by Country (2027-2032) Table 42. Illumina Company Information Table 43. Illumina Business Overview Table 44. Illumina Pharmacogenomics Technology (Theranostics & CDx) Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Illumina Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 46. Illumina Recent Development Table 47. F. Hoffmann-La Roche Company Information Table 48. F. Hoffmann-La Roche Business Overview Table 49. F. Hoffmann-La Roche Pharmacogenomics Technology (Theranostics & CDx) Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. F. Hoffmann-La Roche Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 51. F. Hoffmann-La Roche Recent Development Table 52. Agilent Company Information Table 53. Agilent Business Overview Table 54. Agilent Pharmacogenomics Technology (Theranostics & CDx) Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Agilent Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 56. Agilent Recent Development Table 57. Abbott Company Information Table 58. Abbott Business Overview Table 59. Abbott Pharmacogenomics Technology (Theranostics & CDx) Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Abbott Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 61. Abbott Recent Development Table 62. Thermo Fisher Scientific Company Information Table 63. Thermo Fisher Scientific Business Overview Table 64. Thermo Fisher Scientific Pharmacogenomics Technology (Theranostics & CDx) Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Thermo Fisher Scientific Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 66. Thermo Fisher Scientific Recent Development Table 67. Qiagen Company Information Table 68. Qiagen Business Overview Table 69. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 71. Qiagen Recent Development Table 72. Guardant Health Company Information Table 73. Guardant Health Business Overview Table 74. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 76. Guardant Health Recent Development Table 77. MGI Tech Company Information Table 78. MGI Tech Business Overview Table 79. MGI Tech Pharmacogenomics Technology (Theranostics & CDx) Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. MGI Tech Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 81. MGI Tech Recent Development Table 82. Amoy Diagnostics Company Information Table 83. Amoy Diagnostics Business Overview Table 84. Amoy Diagnostics Pharmacogenomics Technology (Theranostics & CDx) Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Amoy Diagnostics Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 86. Amoy Diagnostics Recent Development Table 87. BGI Group Company Information Table 88. BGI Group Business Overview Table 89. BGI Group Pharmacogenomics Technology (Theranostics & CDx) Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. BGI Group Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 91. BGI Group Recent Development Table 92. Research Programs/Design for This Report Table 93. Authors List of This Report Table 94. Secondary Sources Table 95. Primary Sources List of Figures Figure 1. Pharmacogenomics Technology (Theranostics & CDx) Product Image Figure 2. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 4. Global Pharmacogenomics Technology (Theranostics & CDx) Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Instruments Image Figure 8. Reagents and Consumables Image Figure 9. Other Image Figure 10. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type (2021-2032) Figure 13. Tumour Image Figure 14. Diabetes Image Figure 15. Mental Illness Image Figure 16. Cardiovascular Disease Image Figure 17. Other Image Figure 18. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application (2021-2032) Figure 21. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Pharmacogenomics Technology (Theranostics & CDx) Sales Value (2021-2032) & (US$ Million) Figure 24. North America Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Pharmacogenomics Technology (Theranostics & CDx) Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Pharmacogenomics Technology (Theranostics & CDx) Sales Value (2021-2032) & (US$ Million) Figure 30. South America Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Instruments
  • Reagents and Consumables
  • Other
Applications
  • Tumour
  • Diabetes
  • Mental Illness
  • Cardiovascular Disease
  • Other
Companies covered
  • Illumina
  • F. Hoffmann-La Roche
  • Agilent
  • Abbott
  • Thermo Fisher Scientific
  • Qiagen
  • Guardant Health
  • MGI Tech
  • Amoy Diagnostics
  • BGI Group

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Pharmacogenomics Technology (Theranostics & CDx) Market Dynamics
  1. 2.1 Pharmacogenomics Technology (Theranostics & CDx) Industry Trends
  2. 2.2 Pharmacogenomics Technology (Theranostics & CDx) Industry Drivers
  3. 2.3 Pharmacogenomics Technology (Theranostics & CDx) Industry Opportunities and Challenges
  4. 2.4 Pharmacogenomics Technology (Theranostics & CDx) Industry Restraints
3 Pharmacogenomics Technology (Theranostics & CDx) Market by Company
  1. 3.1 Global Pharmacogenomics Technology (Theranostics & CDx) Company Revenue Ranking in 2025
  2. 3.2 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Company (2021-2026)
  3. 3.3 Global Pharmacogenomics Technology (Theranostics & CDx) Company Ranking (2024-2026)
  4. 3.4 Global Pharmacogenomics Technology (Theranostics & CDx) Company Manufacturing Base and Headquarters
  5. 3.5 Global Pharmacogenomics Technology (Theranostics & CDx) Company Product Type and Application
  6. 3.6 Global Pharmacogenomics Technology (Theranostics & CDx) Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Pharmacogenomics Technology (Theranostics & CDx) Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Pharmacogenomics Technology (Theranostics & CDx) Market by Type
  1. 4.1 Pharmacogenomics Technology (Theranostics & CDx) Type Introduction
  2. 4.1.1 Instruments
  3. 4.1.2 Reagents and Consumables
  4. 4.1.3 Other
  5. 4.2 Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Type
  6. 4.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Type (2021-2032)
  8. 4.2.3 Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type (2021-2032)
5 Pharmacogenomics Technology (Theranostics & CDx) Market by Application
  1. 5.1 Pharmacogenomics Technology (Theranostics & CDx) Application Introduction
  2. 5.1.1 Tumour
  3. 5.1.2 Diabetes
  4. 5.1.3 Mental Illness
  5. 5.1.4 Cardiovascular Disease
  6. 5.1.5 Other
  7. 5.2 Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Application
  8. 5.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Application (2021-2032)
  10. 5.2.3 Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application (2021-2032)
6 Pharmacogenomics Technology (Theranostics & CDx) Regional Value Analysis
  1. 6.1 Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Region (2021-2032)
  3. 6.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Region: 2021-2026
  4. 6.2.2 Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pharmacogenomics Technology (Theranostics & CDx) Sales Value (2021-2032)
  7. 6.3.2 North America Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Sales Value (2021-2032)
  10. 6.4.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Pharmacogenomics Technology (Theranostics & CDx) Sales Value (2021-2032)
  16. 6.6.2 South America Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Country, 2025 VS 2032
7 Pharmacogenomics Technology (Theranostics & CDx) Country-level Value Analysis
  1. 7.1 Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Country (2021-2032)
  3. 7.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Country (2021-2026)
  4. 7.2.2 Global Pharmacogenomics Technology (Theranostics & CDx) Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Pharmacogenomics Technology (Theranostics & CDx) Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Pharmacogenomics Technology (Theranostics & CDx) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Illumina
  2. 8.1.1 Illumina Company Information
  3. 8.1.2 Illumina Business Overview
  4. 8.1.3 Illumina Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Illumina Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  6. 8.1.5 Illumina Recent Developments
  7. 8.2 F. Hoffmann-La Roche
  8. 8.2.1 F. Hoffmann-La Roche Company Information
  9. 8.2.2 F. Hoffmann-La Roche Business Overview
  10. 8.2.3 F. Hoffmann-La Roche Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2021-2026)
  11. 8.2.4 F. Hoffmann-La Roche Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  12. 8.2.5 F. Hoffmann-La Roche Recent Developments
  13. 8.3 Agilent
  14. 8.3.1 Agilent Company Information
  15. 8.3.2 Agilent Business Overview
  16. 8.3.3 Agilent Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Agilent Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  18. 8.3.5 Agilent Recent Developments
  19. 8.4 Abbott
  20. 8.4.1 Abbott Company Information
  21. 8.4.2 Abbott Business Overview
  22. 8.4.3 Abbott Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Abbott Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  24. 8.4.5 Abbott Recent Developments
  25. 8.5 Thermo Fisher Scientific
  26. 8.5.1 Thermo Fisher Scientific Company Information
  27. 8.5.2 Thermo Fisher Scientific Business Overview
  28. 8.5.3 Thermo Fisher Scientific Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Thermo Fisher Scientific Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  30. 8.5.5 Thermo Fisher Scientific Recent Developments
  31. 8.6 Qiagen
  32. 8.6.1 Qiagen Company Information
  33. 8.6.2 Qiagen Business Overview
  34. 8.6.3 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  36. 8.6.5 Qiagen Recent Developments
  37. 8.7 Guardant Health
  38. 8.7.1 Guardant Health Company Information
  39. 8.7.2 Guardant Health Business Overview
  40. 8.7.3 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  42. 8.7.5 Guardant Health Recent Developments
  43. 8.8 MGI Tech
  44. 8.8.1 MGI Tech Company Information
  45. 8.8.2 MGI Tech Business Overview
  46. 8.8.3 MGI Tech Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2021-2026)
  47. 8.8.4 MGI Tech Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  48. 8.8.5 MGI Tech Recent Developments
  49. 8.9 Amoy Diagnostics
  50. 8.9.1 Amoy Diagnostics Company Information
  51. 8.9.2 Amoy Diagnostics Business Overview
  52. 8.9.3 Amoy Diagnostics Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Amoy Diagnostics Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  54. 8.9.5 Amoy Diagnostics Recent Developments
  55. 8.10 BGI Group
  56. 8.10.1 BGI Group Company Information
  57. 8.10.2 BGI Group Business Overview
  58. 8.10.3 BGI Group Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2021-2026)
  59. 8.10.4 BGI Group Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  60. 8.10.5 BGI Group Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst